Cannabinoid Therapy Gains Foothold in Germany’s Epilepsy Market Argent BioPharma (ASX:RGT) has secured approval for its flagship cannabinoid-based epilepsy treatment, CannEpil™, to be prescribed in Germany. This milestone marks a major step in the company’s European expansion and strengthens its presence in one of the region’s key pharmaceutical markets. Germany has approximately 816,000 epilepsy patients,
Read More
Enmore Gold Project Shows Exploration Potential Koonenberry Gold (ASX:KNB) has returned high-grade gold intercepts from its first diamond drillhole at the Enmore Gold Project in northeast New South Wales. The results validate historical drill data and highlight the potential for a significant mineralised system. Managing Director Dan Power described the outcome as “a truly exciting
Read More
Property Market Shift Opens Opportunities Australia’s property sector continues to attract strong investor interest, with major players eyeing strategic acquisitions. AVJennings Limited (ASX:AVJ) has now entered into a Scheme Implementation Deed (SID) with AVID Property Group, in partnership with Proprium Capital Partners, in a deal valued at $0.655 per share. This agreement provides a significant
Read More
The RBA’s benchmark interest rate was left unchanged at 4.10% at the Bank’s 31 March-1 April Board meeting, with our central bank deciding to leave well enough alone ahead of a swag of political and economic uncertainties hitting markets over coming weeks. This left the RBA rate a touch under the existing US Fed Funds
Read More
Funding Agreement with Deutsche Balaton AG Altech Batteries (ASX:ATC) has entered into a bearer bond agreement with major shareholder Deutsche Balaton AG, allowing the company to access up to €2.5 million in funding. The agreement, which requires shareholder approval, will provide cash in increments of €500,000. The interest payable on the bearer bonds will be
Read More
Fertility Tech Market Expands, With Memphasys Ready to Capitalise The global assisted reproductive technology (ART) sector continues to grow rapidly, with IVF cycles projected to exceed 4 million annually by 2030. The demand for technologies that improve embryo success rates is stronger than ever — and Memphasys (ASX:MEM) with its Felix™ System appears poised to
Read More
